In this issue:
Risk factors of subsequent primary melanomas in Austria
Treatment of melanoma at high-volume facilities is associated with improved long-term survival
Relative survival of melanoma between histologic subtypes
Glembatumumab vedotinin treatment for advanced melanoma
ctDNA for prediction and monitoring of relapse in stage III melanoma
Pre-operative ctDNA predicts survival in high-risk stage III melanoma
Sentinel node for malignant melanoma
Real-world impact of modern treatments on survival of patients with MM
Association of HLA antigen mismatch with risk of skin cancer after solidorgan transplant
A nomogram to identify high-risk melanoma patients with a negative SNLB
Please login below to download this issue (PDF)